Comprehensive Analysis of Perioperative Factors Influencing the Risk of Biochemical Recurrence in Patients with Radical Prostatectomy.
Urology journal./Urology jornal. · 06.05.2024 · 21 (3) · 162-168
DOI: 10.22037/uj.v20i.7835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urology journal./Urology jornal., erschienen am 06.05.2024. Verfasst von Mihnea Bogdan Borz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Oncology "Prof dr. Ion Chiricuta" CLUJ NAPOCA. borz.m.bogdan@gmail.com. Hauptthemen laut MEDLINE: Prostatectomy, Prostatic Neoplasms, Neoplasm Recurrence, Local, Prostate-Specific Antigen.
Abstract (Originalsprache)
PURPOSE: To analyze the perioperative factors that influence the risk of biochemical recurrence (BCR) in patients with localized PCa undergoing radical prostatectomy Materials and Methods: A total of 457 patients, operated by 2 surgeons in our high-volume oncological center were included in the initial database. Patients who underwent RP for clinically localized PCa in our clinic from 2016 to 2021 were included in the study. Perioperative data were retrospectively reviewed for this study. Follow-up data including post-operative PSA and adjuvant treatment was prospectively gathered by contacting the patients or from the follow-up consultation. Final database was composed of 366 patients who underwent open or 3D laparoscopic RP. Statistical analysis was performed to emphasize the most powerful parameters that influence the BCR. Results: Accounting for multivariable analysis, 4 parameters were statistically significant: initial PSA (iPSA), Gleason score, vascular involvement and positive surgical margins. For the group of patients with no positive margins, 3 parameters were statistically significant: iPSA above 10,98 ng/mL (AUC=0,71); lymph node involvement and Gleason score. Multivariable Cox regression showed that positive margins and iPSA had a significant impact on the time to BCR. Patients that received adjuvant therapy were excluded from the study. Out of the whole cohort, 27,3% of patients presented BCR. CONCLUSION: Perioperative factors need to be carefully analyzed and a detailed follow-up needs to be conducted in order to assess the risk of biochemical recurrence, resulting in the optimal time for adjuvant treatment implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Oncology "Prof dr. Ion Chiricuta" CLUJ NAPOCA. borz.m.bogdan@gmail.com.
- Institute of Oncology "Prof dr. Ion Chiricuta" CLUJ NAPOCA. schitcu@yahoo.com.
- "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca. nicolaecrisan@icloud.com.
- Institute of Oncology "Prof dr. Ion Chiricuta" CLUJ NAPOCA. bogdanpetrut@gmail.com.
- Târgu Mureș County Emergency Clinical Hospital. drborzcristian@gmail.com.
- Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor, Cluj Napoca. borz_paul96@yahoo.com.
Zitieren
APA
Borz, M. B., Schitcu, V. H., Crisan, N., Petrut, B., Borz, O. C., Borz, P. C., Duquesne, I., Nasri, J., & Coman, I. (2024). Comprehensive Analysis of Perioperative Factors Influencing the Risk of Biochemical Recurrence in Patients with Radical Prostatectomy. Urology journal./Urology jornal., 21(3), 162-168. https://doi.org/10.22037/uj.v20i.7835
Vancouver
Borz MB, Schitcu VH, Crisan N, Petrut B, Borz OC, Borz PC, et al. Comprehensive Analysis of Perioperative Factors Influencing the Risk of Biochemical Recurrence in Patients with Radical Prostatectomy. Urology journal./Urology jornal.. 2024;21(3):162-168. doi:10.22037/uj.v20i.7835
BibTeX
@article{Borz2024,
author = {Borz, Mihnea Bogdan and Schitcu, Vlad Horia and Crisan, Nicolae and Petrut, Bogdan and Borz, Oliviu Cristian and Borz, Paul Cristian and Duquesne, Igor and Nasri, Jordan and Coman, Ioan},
title = {Comprehensive Analysis of Perioperative Factors Influencing the Risk of Biochemical Recurrence in Patients with Radical Prostatectomy},
journal = {Urology journal./Urology jornal.},
year = {2024},
volume = {21},
number = {3},
pages = {162--168},
doi = {10.22037/uj.v20i.7835}
}
EUVIMED